Optimal dosage of methotrexate for GVHD prophylaxis in umbilical cord blood transplantation.


Journal

International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 22 08 2018
accepted: 16 01 2019
revised: 28 12 2018
pubmed: 27 1 2019
medline: 18 4 2019
entrez: 26 1 2019
Statut: ppublish

Résumé

The combination of methotrexate (MTX) and a calcineurin inhibitor is widely used for GVHD prophylaxis in umbilical cord blood transplantation (UCBT). However, the optimal MTX dosage for GVHD prophylaxis in UCBT remains unclear. In the present study, we investigated the impact of MTX dosage on clinical outcomes following UCBT in a single-center retrospective study. Of 70 UCBT recipients included in this study, 37 received MTX at doses of 10 mg/m

Identifiants

pubmed: 30680665
doi: 10.1007/s12185-019-02598-x
pii: 10.1007/s12185-019-02598-x
doi:

Substances chimiques

Tacrolimus WM0HAQ4WNM
Methotrexate YL5FZ2Y5U1

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

440-450

Références

Am J Respir Crit Care Med. 2002 Sep 1;166(5):641-5
pubmed: 12204858
Blood. 2003 Mar 15;101(6):2137-43
pubmed: 12424197
Bone Marrow Transplant. 2002 Dec;30(12):937-43
pubmed: 12476288
Br J Haematol. 2003 Feb;120(3):516-22
pubmed: 12580971
Biol Blood Marrow Transplant. 2003 Dec;9(12):772-80
pubmed: 14677117
Blood. 2004 Dec 1;104(12):3813-20
pubmed: 15280199
Blood. 2005 Feb 15;105(4):1408-16
pubmed: 15486071
N Engl J Med. 2004 Nov 25;351(22):2265-75
pubmed: 15564543
N Engl J Med. 2004 Nov 25;351(22):2276-85
pubmed: 15564544
Biol Blood Marrow Transplant. 2005 Feb;11(2):149-60
pubmed: 15682076
Transplantation. 2005 Jul 15;80(1):34-40
pubmed: 16003230
Bone Marrow Transplant. 2006 Sep;38(6):421-6
pubmed: 16892072
Bone Marrow Transplant. 2006 Oct;38(8):539-46
pubmed: 16953207
Bone Marrow Transplant. 2007 Jan;39(1):31-9
pubmed: 17115066
Blood. 2009 Feb 19;113(8):1631-8
pubmed: 19104080
Bone Marrow Transplant. 2009 Jul;44(1):43-9
pubmed: 19139727
Bone Marrow Transplant. 2009 Nov;44(10):661-6
pubmed: 19802029
Biol Blood Marrow Transplant. 2009 Nov;15(11):1485-8
pubmed: 19822310
Lancet Oncol. 2010 Jul;11(7):653-60
pubmed: 20558104
Transplantation. 2010 Oct 27;90(8):918-26
pubmed: 20717073
Blood. 2011 Aug 11;118(6):1685-92
pubmed: 21636856
Transplantation. 2011 Aug 15;92(3):366-71
pubmed: 21677598
Biol Blood Marrow Transplant. 2012 May;18(5):780-7
pubmed: 22008851
J Clin Oncol. 2012 Feb 1;30(4):441-4
pubmed: 22184396
Bone Marrow Transplant. 2012 Nov;47(11):1459-64
pubmed: 22410750
Biol Blood Marrow Transplant. 2013 Jan;19(1):22-7
pubmed: 23041600
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Blood. 2013 Jul 25;122(4):491-8
pubmed: 23673863
Bone Marrow Transplant. 2014 Feb;49(2):248-53
pubmed: 24162612
Biol Blood Marrow Transplant. 2014 Sep;20(9):1335-40
pubmed: 24796281
Biol Blood Marrow Transplant. 2015 Feb;21(2):305-11
pubmed: 25464119
Biol Blood Marrow Transplant. 2015 May;21(5):920-5
pubmed: 25687796
Int J Hematol. 2015 May;101(5):467-86
pubmed: 25864188
Pediatr Transplant. 2016 Feb;20(1):114-9
pubmed: 26526424
Biol Blood Marrow Transplant. 2016 Apr;22(4):744-751
pubmed: 26762681
Int J Hematol. 2016 Jul;104(1):117-24
pubmed: 27119977
Bone Marrow Transplant. 2016 Dec;51(12):1588-1593
pubmed: 27400068
Int J Hematol. 2017 Jan;105(1):92-99
pubmed: 27686673
Mediterr J Hematol Infect Dis. 2016 Oct 18;8(1):e2016051
pubmed: 27872731
Bone Marrow Transplant. 2017 Mar;52(3):423-430
pubmed: 27941766
Mol Med Rep. 2017 Apr;15(4):2353-2359
pubmed: 28259947
Bone Marrow Transplant. 2017 Sep;52(9):1261-1267
pubmed: 28604665
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Ann Intern Med. 1993 Feb 15;118(4):255-67
pubmed: 8420443
Am Rev Respir Dis. 1993 Jun;147(6 Pt 1):1601-6
pubmed: 8503576
Stat Med. 1997 Apr 30;16(8):901-10
pubmed: 9160487
Ann Hematol. 1997 May;74(5):221-4
pubmed: 9200994

Auteurs

Yoshitaka Adachi (Y)

Department of Hematology and Oncology, Konan Kosei Hospital, 137, Omatsubara,Takaya-cho, Konan, 483-8704, Aichi, Japan. adachi_y0216@yahoo.co.jp.

Kazutaka Ozeki (K)

Department of Hematology and Oncology, Konan Kosei Hospital, 137, Omatsubara,Takaya-cho, Konan, 483-8704, Aichi, Japan.

Shun Ukai (S)

Department of Hematology and Oncology, Konan Kosei Hospital, 137, Omatsubara,Takaya-cho, Konan, 483-8704, Aichi, Japan.

Ken Sagou (K)

Department of Hematology and Oncology, Konan Kosei Hospital, 137, Omatsubara,Takaya-cho, Konan, 483-8704, Aichi, Japan.

Nobuaki Fukushima (N)

Department of Hematology and Oncology, Konan Kosei Hospital, 137, Omatsubara,Takaya-cho, Konan, 483-8704, Aichi, Japan.

Akio Kohno (A)

Department of Hematology and Oncology, Konan Kosei Hospital, 137, Omatsubara,Takaya-cho, Konan, 483-8704, Aichi, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH